Awad was recruited in 2010 to lead the Neurovascular Surgery Program at the University of Chicago Medicine, and is currently tenured in the Biological Sciences Division. He is the John Harper Seeley Professor of Neurological Sciences and Professor of Neurological Surgery, Neurology, the Grossman Institute of Neuroscience, Quantitative Biology and Human Behavior, and the (PhD granting) Committee on Neurobiology. He is a Senior Faculty Scholar at the Bucksbaum Institute for Clinical Excellence and directs the Safadi Program of Excellence in Clinical and Translational Neurosciences. Dr Awad is active in numerous professional and learned societies. He has served on the Executive Committee of the American Stroke Association, and on the Board of Governors of the American College of Surgeons. He was the Chairman of the Joint Cerebrovascular Section of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons, he has directed the Annual Course on Research Update in Neuroscience for Neurosurgeons, and he served as the 51st President of the Congress of Neurological Surgeons. Dr Awad is the Founding past-President of the World Association of Lebanese Neurosurgeons, and the Founding Chairman of Scientific Advisory Board of the patient advocacy group Angioma Alliance.
Dr Awad has authored over 350 scientific papers and book chapters, and edited twelve books dealing with cerebrovascular surgery and other aspects of neurological surgery. He has presented over 500 papers and lectures at major meetings and symposia, has been a visiting professor at numerous institutions in the United States and abroad, was recognized among America’s Best Doctors, Best Teachers, and is the recipient of the Bucy Award for Excellence in Neurosurgical Education, the Arnold Award for Mentoring at Pritzker School of Medicine, and numerous other honors. Dr Awad has made numerous scientific contributions including the characterization of subcortical ischemic lesions in the aged, advances in the understanding of the natural history and biologic behavior of vascular malformations of the brain, numerous technical advances in neurovascular and epilepsy surgery, and is a recognized expert in the treatment of neurovascular disease, hemorrhagic stroke and neurosurgical critical care. His research has been cited by other researchers more than 79,000 times (H-index 91). Current research focuses on molecular mechanisms, biomarkers and therapeutic targets in cavernous angiomas (cerebral vascular malformations), the pathobiology of brain hemorrhage, and minimally invasive techniques for treating hemorrhagic stroke.
Dr. Awad's research has been funded continuously from the National Institutes of Health since 1998, including a prestigious midcareer development grant in patient-oriented research (2000-2005), and current active R01, P01 and U01 funding through 2025. From 2016 to 2020, he served on the United States National Advisory Council for Neurological Disorders and Stroke. In 2019, he was elected to the Association of American Physicians.
www.issamawad.com
www.uchicagomedicine.org/ccm
www.uchicagomedicine.org/hht
http://safadiprogram.uchicago.edu
Barrow Neurological Institute
AZ
Neurovascular surgery fellowship
Royal Infirmary of Edinburgh
Scotland
Neurotraumatology fellowship
Cleveland Clinic
OH
Neurosurgical residency
Loma Linda University
CA
MD
Loma Linda University
CA
MS
Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations.
Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations. Nat Commun. 2023 Nov 02; 14(1):7009.
PMID: 37919320
Computer-Supervised EVD Raises Safety Questions in ICU Care of IVH: Humans-1, Computers-0.
Computer-Supervised EVD Raises Safety Questions in ICU Care of IVH: Humans-1, Computers-0. JAMA Netw Open. 2023 10 02; 6(10):e2335184.
PMID: 37815834
mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice.
mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice. Stroke. 2023 Nov; 54(11):2906-2917.
PMID: 37746705
Corrigendum to "Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu" [J. Autoimmun. 113 (2020) 102469].
Corrigendum to "Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu" [J. Autoimmun. 113 (2020) 102469]. J Autoimmun. 2023 Sep 23; 103116.
PMID: 37748978
Catheter Tract Hemorrhages and Intracerebral Hemorrhage Outcomes in the Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Trial.
Catheter Tract Hemorrhages and Intracerebral Hemorrhage Outcomes in the Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Trial. Neurosurgery. 2023 Sep 18.
PMID: 37721435
Inflammatory Mechanisms in a Neurovascular Disease: Cerebral Cavernous Malformation.
Inflammatory Mechanisms in a Neurovascular Disease: Cerebral Cavernous Malformation. Brain Sci. 2023 Sep 17; 13(9).
PMID: 37759937
Minimally Invasive Surgery With Thrombolysis for Intracerebral Hemorrhage Evacuation: Bayesian Reanalysis of a Randomized Controlled Trial.
Minimally Invasive Surgery With Thrombolysis for Intracerebral Hemorrhage Evacuation: Bayesian Reanalysis of a Randomized Controlled Trial. Neurology. 2023 Oct 17; 101(16):e1614-e1622.
PMID: 37684058
Underlying intracranial atherosclerotic disease is associated with worse outcomes in acute large vessel occlusion undergoing endovascular thrombectomy.
Underlying intracranial atherosclerotic disease is associated with worse outcomes in acute large vessel occlusion undergoing endovascular thrombectomy. J Stroke Cerebrovasc Dis. 2023 Aug; 32(8):107227.
PMID: 37437522
Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling.
Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling. medRxiv. 2023 Jun 05.
PMID: 37333396
Impact of socioeconomics and race on clinical follow-up and trial enrollment and adherence in cerebral cavernous malformation.
Impact of socioeconomics and race on clinical follow-up and trial enrollment and adherence in cerebral cavernous malformation. J Stroke Cerebrovasc Dis. 2023 Jul; 32(7):107167.
PMID: 37146402